Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 795-804

  Mele, Teresa ^a,b   Generali, Daniele ^b   Fox, Stephen ^e   Brizzi, Maria Pia ^a   Bersiga, Alessandra ^a   Milani, Manuela ^b   Allevi, Giovanni ^b   Bonardi, Simone ^b   Aguggini, Sergio ^b   Volante, Marco ^c   Dogliotti, Luigi ^a   Bottini, Alberto ^a,b   Harris, Adrian ^d   Berruti, Alfredo ^b  

^a Oncologia Medica   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Angiogenesis; Breast cancer; Epirubicin; Tamoxifen; VEGF; VEGFR2

Indexed keywords

CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TREATMENT RESPONSE; BREAST TUMOR; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; ITALY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79952115609     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1063-0     Document Type: Article

References (32)

1. Carlson RW, Hudis Ca, Pritchard KI (2006) Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Cancer Netw 4(10):971-979 (Pubitemid 44845487)
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Panel members, thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 20: 1319-1329
3. Albain KS, Green SJ, Ravdin PM et al (2002) Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a (abstract 143)
4. Garvin S, Nilsson UW, Dabrosin C (2005) Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93(9): 1005-1010 (Pubitemid 41548394)
5. Haran EF, Maretzek AF, Goldberg I, Horowitz A, Degani H (1994) Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511-5514 (Pubitemid 24346235)
6. Lindner DJ, Borden EC (1997) Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71:456-461 (Pubitemid 27224313)
7. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA (2002) An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62:4678-4684
8. Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63:8742-8748 (Pubitemid 38064052)
9. Elkin M, Orgel A, Kleinman HK (2004) An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 96:875-878 (Pubitemid 38807609)
10. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617:437-444
11. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049 (Pubitemid 351656458)
12. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676 (Pubitemid 36749215)
13. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974 (Pubitemid 43093963)
14. Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39(5):469-478 (Pubitemid 44714526)
15. Rydén L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G (2003) Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82:147-154 (Pubitemid 37521970)
16. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9-22 (Pubitemid 29038270)
17. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536-550 (Pubitemid 47351464)
18. Bottini A, Berruti A, Brizzi MP et al (2005) Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: A single-institution phase III trial. Endocr Relat Cancer 12(2):383-392 (Pubitemid 40896453)
19. Lee AHS, Ellis IO (2009) The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol Oncol Res 14:113-115
20. Bottini A, Berruti A, Bersiga A et al (2000) p53 but not bcl-2 immunostaining is predictive of poor complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6:2751-2758 (Pubitemid 30482114)
21. Generali D, Buffa F, Berruti A et al (2009) Phosphorylated ER, HIF-1, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 27(2):227-234
22. Fox SB, Braganca J, Turley H et al (2004) CITED4 inhibits hypoxia-Activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res 64:6075-6081 (Pubitemid 39129407)
23. Bottini A, Berruti A, Bersiga A et al (2002) Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 8: 1816-1821 (Pubitemid 34633740)
24. Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623-3628 (Pubitemid 46630536)
25. Baar J, Silverman P, Lyons J et al (2009) A vasculature-Targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 15(10):3583-3590
26. Foekens JA, Peters HA, Grebenchtchikov N et al (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414 (Pubitemid 32694919)
27. Linderholm BK, Lindahl T, Holmberg L et al (2001) The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61:2256-2260 (Pubitemid 32692056)
28. Gasparini G, Toi M, Gion M et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139-147 (Pubitemid 27034790)
29. Gasparini GP, Toi M, Verderio P et al (1998) Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and nodenegative patients. Int J Oncol 12:1117-1125
30. Konecny GE, Meng YG, Untch M et al (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706-1716 (Pubitemid 38435562)
31. Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639-1646
32. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37-44 (Pubitemid 30225456)